Clinical trials: Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA)
Methotrexate-Inadequate Response Study
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an…
- Trial name
- NCT00559585
- Testing
- Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept
- Where
- 203 sites in United States, Argentina and 22 more
- Volunteers
- 2,492 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis (RA)
Phase IIIB Subcutaneous Abatacept Monotherapy Study
To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept
- Trial name
- NCT00547521
- Testing
- abatacept, Methotrexate (MTX)
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 119 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis (RA)
Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient
To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).
- Trial name
- NCT01871961
- Testing
- Methotrexate (Metoject® prefilled pen)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- medac GmbH
Rheumatoid Arthritis (RA)
Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
Relative Bioavailability Comparison study
- Trial name
- NCT01618968
- Testing
- MTX
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Antares Pharma Inc.
Rheumatoid Arthritis (RA)
Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
The purpose of this study is to assess the usability of the VIBEX MTX device for SC self-injection of methotrexate.
- Trial name
- NCT01618955
- Testing
- VIBEX MTX
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Antares Pharma Inc.
Rheumatoid Arthritis（RA）
Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients
A prospective, multi-centric, cohort study to observe the efficacy difference between intensive classic DMARDs and Infliximab(IFX) with methotrexate(MTX) treatment in sever rheumatoid arthritis(RA) 28 joints disease activity…
- Trial name
- INNOVATION (NCT01915537)
- Testing
- Infliximab group, Classic DMARDs treatment group
- Where
- 3 sites in China
- Volunteers
- 170 people
- Sponsor
- Zhang, Xiao, M.D.
Osteoarthritis (OA), Rheumatoid Arthritis (RA)
Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).
RATIONAL is a multinational, multicentre, observational, cross sectional study of adult patients in treatment with NSAID therapy for OA, RA or AS during for at least 2 weeks before study visit (at least one dose).
- Conditions
- Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS)
- Trial name
- RATIONAL (NCT01577563)
- Where
- 85 sites in Argentina, Colombia and 8 more
- Volunteers
- 5,383 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis (RA)
Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.
The purpose of this study is to assess the clinical response to IL-6 inhibition defined as Low Disease Activity (DAS44) <2.4) at the follow-up visit at 12 months and the correlation between the biomarkers and treatment response.
- Trial name
- NCT01835613
- Testing
- Biomarkers Measures
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Osservatorio Epidemiologico GISEA
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA
EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries
This is a non-interventional, post-marketing, observational study (PMOS) in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA, Rheumatoid Arthritis (RA
- Trial name
- EviraEAST (NCT01078402)
- Where
- 163 sites in Croatia, Hungary and 5 more
- Volunteers
- 809 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis (RA)
Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients
This is a Phase III study to evaluate efficacy and safety of Tocilizumab in patients with Rheumatoid Arthritis.
- Trial name
- NCT01258712
- Testing
- Tocilizumab + methotrexate(MTX)
- Where
- 12 sites in Taiwan
- Volunteers
- 86 people
- Sponsor
- Chugai Pharma Taiwan
Rheumatoid Arthritis (RA)
Optimization of Treatment With Adalimumab (Humira)
The purpose of this trial is to assess the effect of two Intensive Outpatient Management Strategies (IOMS) versus Routine Care (RC) on the outcomes of patients with Rheumatoid Arthritis (RA) that are treated with adalimumab.
- Trial name
- NCT01585064
- Testing
- DAS28-IOMS, 0SJ-IOMS, Routine Care (RC)
- Where
- Canada
- Volunteers
- 309 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Rheumatoid Arthritis (RA)
Methotrexate - Inadequate Response Device Sub-Study
The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.
- Trial name
- MTX-IR (NCT01173120)
- Testing
- Abatacept combination product (ACP)
- Volunteers
- 62 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis (RA)
Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment With SMP-114
To compare the efficacy of SMP-114 (120 and 240 mg/d) versus placebo in terms of the percentage of patients meeting the American College of Rheumatology criteria for 20% improvement in RA (ACR20) at week 24.
- Trial name
- NCT00296257
- Testing
- SMP-114
- Where
- 46 sites in Czechia, Germany and 4 more
- Volunteers
- 312 people
- Sponsor
- Dainippon Sumitomo Pharma Europe LTd.